[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649121":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":50,"collaborators":52,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":24,"maxAge":24,"enrollmentInfo":65,"targetDuration":24,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":84,"whyStopped":24,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Sao Paulo General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Annual IGRA Rescreening","EXPERIMENTAL","Patients will undergo repeated IGRA annually for 3 years after an initial negative screening. Baseline screening includes epidemiologic questionnaire, chest X-ray and interferon-gamma release assay (IGRA).\n\nPatients with new positive results will be investigated (chest X ray and clinical synthons) for TBD. If negative, they will receive TBI indicated treatment.",[13],"Other: re-screening",{"label":15,"type":6,"description":16,"interventionNames":17},"No Rescreening","Patients will not repeat annual TB screening after the baseline negative evaluation (except in cases before the initiation of advanced therapy). They will continue standard clinical follow-up and monitoring for TBD symptoms.",[18],"Other: No Rescreening",[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"re-screening","Routine annual TB re-screening after negative (IGRA)",[9],null,{"type":6,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Standard clinical follow-up without routine annual TB re-screening",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Eloisa SDO Bonfa, Full Professor","CONTACT","+55 11 3061-7490","reumatologia.fmusp@hc.fm.usp.br",[35],{"facility":36,"status":24,"city":37,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Rheumatology Division, Faculdade de Medicina da USP, São Paulo, SP","São Paulo","01246-903","Brazil","BR",{"type":42,"coordinates":43},"Point",[44,45],-46.63611,-23.5475,{"lat":45,"lon":44},[48],{"name":30,"role":31,"phone":49,"phoneExt":24,"email":33},"+55 11 2661-8806",{"type":51,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[53],{"name":54,"class":55},"Fundação de Amparo à Pesquisa do Estado de São Paulo","OTHER_GOV","100649121","incidence-of-tuberculosis-in-patients-with-autoimmune-rheumatic-diseases-100649121",false,"NCT07731672","Incidence of Tuberculosis in Patients With Autoimmune Rheumatic Diseases","Prospective Randomized Controlled Study to Evaluate the Effectiveness of Annual Tuberculosis Re-Screening in Patients With Autoimmune Rheumatic Diseases Receiving Biologic and\u002For Immunosuppressive Therapy","TB-RESCREEN","Inclusion Criteria:\n\n* Patients (adults and children) diagnosed with autoimmune rheumatic diseases according to established international classification criteria\n* negative baseline screening for tuberculosis infection.\n\nExclusion Criteria:\n\n* History of tuberculosis infection or disease\n* Radiographic evidence suggestive of prior TB\n* Previous treatment for TBD or TBI\n* Positive baseline TB screening;\n* Follow-up shorter than 12 months","ALL",{"count":66,"type":67},1660,"ESTIMATED","INTERVENTIONAL",[70],"NA","This is a prospective, randomized, controlled study designed to evaluate the effectiveness of annual re-screening for tuberculosis infection (TBI) (previous) in patients with autoimmune rheumatic diseases (ARDs) receiving biologic and\u002For immunosuppressive therapy.\n\nPatients with negative baseline TBI screening will be randomized to undergo annual re-screening using interferon-gamma release assay (IGRA) or to a control group without routine re-screening.\n\nPatients with newly detected TBI will receive preventive treatment. The primary objective is to assess whether annual re-screening combined with TBI treatment reduces the incidence of active tuberculosis. Secondary objectives include determining TBI conversion rates and identifying risk factors for infection.",[73,74],"Autoimmune Rheumatic Diseases","Prevention",[76,77,78,73,79,80,81,82,74,83],"Tuberculosis","Tuberculosis disease","Tuberculosis infection","Biologic Therapy","Screening","IGRA","Rheumatology","Prospective Study","NOT_YET_RECRUITING","2026-08-14",{"date":87,"type":88},"2026-08-18","ACTUAL",{"date":90,"type":67},"2026-08-01",{"date":92,"type":67},"2031-07-30",{"name":5,"class":6},1]